Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | PPARA | Q07869 | 3/20 | 0.37 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18631777 | 0.88 | PAM (0.42) | ADRB2ADRB1ADRB3ALDH1A1LMNA | |
| SCHEMBL18631743 | 0.86 | PPARA (0.46) | ADRB2ADRB1ADRB3ALDH1A1LMNA | |
| SCHEMBL18650334 | 0.86 | CTSL (0.41) | ACEALDH1A1PPARGPPARATSHR | |
| SCHEMBL20122588 | 0.83 | ACE (0.48) | ACEADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL18650338 | 0.82 | MME (0.35) | ACEALDH1A1LMNAMME | |
| SCHEMBL18650346 | 0.82 | PPARG (0.41) | ACEALDH1A1LMNAPPARGPPARA | |
| SCHEMBL20122445 | 0.82 | ADRB2 (0.41) | ACEADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL18650356 | 0.81 | MME (0.35) | ACEALDH1A1LMNAMME | |
| SCHEMBL18650339 | 0.80 | ACE (0.36) | ACEMME | |
| SCHEMBL20122382 | 0.79 | ADRB2 (0.38) | ACEADRB2ADRB1ADRB3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630918-B2 | Cysteine, N-acetylcysteine, and penicillamine related compounds, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630918-B2 | Cysteine, N-acetylcysteine, and penicillamine related compounds, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2017-04-25 | — | — | US | disclosed |
| US-20170081280-A1 | CYSTEINE, N-ACETYLCYSTEINE, AND PENICILLAMINE RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170081280-A1 | CYSTEINE, N-ACETYLCYSTEINE, AND PENICILLAMINE RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081280-A1 | CYSTEINE, N-ACETYLCYSTEINE, AND PENICILLAMINE RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | NAT1, HHAT, CBS | ACE 917/4885ADRB2 862/4885ADRB1 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.